Business
Regentis Biomaterials Ltd. Announces Closing of Initial Public Offering
Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gros
About this update from Regentis Biomaterials Ltd.
[{"type":"image","alt":"Regentis Biomaterials Ltd.","displaySize":"","headline":null,"caption":"Regentis Biomaterials Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":77,"url":"https://media.zenfs.com/en/globenewswire.com/8caad25dbe73fc33f0bde8b5e70a39e9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FBK6XQbD_lS4FRwkuI60VQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8caad25dbe73fc33f0bde8b5e70a39e9","width":300,"height":77}},"lazy":false},{"type":"text","content":"Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 187,500 Ordinary Shares to cover over-allotments, if any.","length":767,"tagName":"p"},{"type":"text","content":"The Ordinary Shares began trading on the NYSE American LLC on December 4, 2025, under the symbol “RGNT”.","length":104,"tagName":"p"},{"type":"text","content":"The Company intends to use the net proceeds from the Offering primarily for development activities, including the completion of its pivotal trial, and preparation of the PMA submission for GerlinC, and also for corporate purposes including the repayment of certain debt and deferred compensation payments.","length":305,"tagName":"p"},{"type":"text","content":"ThinkEquity acted as sole book-running manager for the Offering.","length":64,"tagName":"p"},{"type":"text","content":"A Registration Statement on Form F-1 (File No. 333-285692) and amendments thereto relating to the Ordinary Shares sold in the Offering was filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective, as amended, on November 12, 2025. The Offering was made only by means of a prospectus. The final prospectus was filed with the SEC and is ava...